BMRN (BioMarin Pharmaceuticals Inc)
Insider Trading Activity
Every open-market purchase and sale reported by BMRN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-04 | ELIZABETH M ANDERSON | Director | A | — | — |
| 2026-06-04 | Barbara W. Bodem | Director | A | — | — |
| 2026-06-04 | IAN T CLARK | Director | A | — | — |
| 2026-06-04 | Willard H Dere | Director | A | — | — |
| 2026-06-04 | Mark J Enyedy | Director | A | — | — |
| 2026-06-04 | ROBERT J. HOMBACH | Director | A | — | — |
| 2026-06-04 | Maykin Ho | Director | A | — | — |
| 2026-06-04 | Timothy P Walbert | Director | A | — | — |
| 2026-06-04 | Athena Countouriotis | Director | A | — | — |
| 2026-05-21 | Cristin Hubbard | EVP, Chief Commercial Officer | F | — | — |
| 2026-05-11 | Gregory R Friberg | EVP, Chief R&D Officer | Sell | — | — |
| 2026-03-19 | Alexander Hardy | Chief Executive Officer | F | — | — |
| 2026-03-19 | Brian Mueller | EVP, Chief Financial Officer | F | — | — |
| 2026-03-19 | Charles Greg Guyer | EVP, Chief Technical Officer | F | — | — |
| 2026-03-19 | George Eric Davis | EVP, Chief Legal Officer | F | — | — |
| 2026-03-18 | Gregory R Friberg | EVP, Chief R&D Officer | MIXED | — | — |
| 2026-03-18 | Cristin Hubbard | EVP, Chief Commercial Officer | MIXED | — | — |
| 2026-03-17 | Alexander Hardy | Chief Executive Officer | MIXED | — | — |
| 2026-03-17 | Brian Mueller | EVP, Chief Financial Officer | MIXED | — | — |
| 2026-03-17 | George Eric Davis | EVP, Chief Legal Officer | MIXED | — | — |
| 2026-03-17 | Charles Greg Guyer | EVP, Chief Technical Officer | MIXED | — | — |
| 2026-03-12 | Charles Greg Guyer | EVP, Chief Technical Officer | Sell | — | — |
| 2026-02-26 | Brian Mueller | EVP, Chief Financial Officer | A | — | — |
| 2026-02-26 | George Eric Davis | EVP, Chief Legal Officer | MIXED | — | — |
| 2026-02-26 | Gregory R Friberg | EVP, Chief R&D Officer | Sell | — | — |
| 2026-02-26 | Charles Greg Guyer | EVP, Chief Technical Officer | A | — | — |
| 2026-01-22 | Rashmi Virendra Ramchandani | VP, Chief Accounting Officer | A | — | — |
| 2025-12-02 | Alexander Hardy | Chief Executive Officer | MIXED | — | — |
| 2025-10-02 | Gregory R Friberg | EVP, Chief R&D Officer | F | — | — |
| 2025-08-05 | IAN T CLARK | Director | A | — | — |
| 2025-05-22 | ELIZABETH M ANDERSON | Director | A | — | — |
| 2025-05-22 | Barbara W. Bodem | Director | A | — | — |
| 2025-05-22 | Athena Countouriotis | Director | A | — | — |
| 2025-05-22 | Willard H Dere | Director | A | — | — |
| 2025-05-22 | Mark J Enyedy | Director | A | — | — |
| 2025-05-22 | Maykin Ho | Director | A | — | — |
| 2025-05-22 | ROBERT J. HOMBACH | Director | A | — | — |
| 2025-05-22 | RICHARD A MEIER | Director | A | — | — |
| 2025-05-22 | Timothy P Walbert | Director | A | — | — |
| 2025-05-22 | Cristin Hubbard | EVP, Chief Commercial Officer | F | — | — |
| 2025-05-20 | Erin Burkhart | GVP, Chief Accounting Officer | MIXED | — | — |
| 2025-05-06 | Cristin Hubbard | EVP, Chief Commercial Officer | MIXED | — | — |
| 2025-03-20 | Erin Burkhart | GVP, Chief Accounting Officer | Sell | — | — |
| 2025-03-18 | Alexander Hardy | Chief Executive Officer | MIXED | — | — |
| 2025-03-18 | Brian Mueller | EVP, Chief Financial Officer | MIXED | — | — |
| 2025-03-18 | Charles Greg Guyer | EVP, Chief Technical Officer | MIXED | — | — |
| 2025-03-18 | Gregory R Friberg | EVP, Chief R&D Officer | A | — | — |
| 2025-03-18 | Cristin Hubbard | EVP, Chief Commercial Officer | A | — | — |
| 2025-03-18 | George Eric Davis | EVP, Chief Legal Officer | MIXED | — | — |
| 2025-03-18 | Erin Burkhart | GVP, Chief Accounting Officer | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 473,892 | — |
| — | Chief Executive Officer | 214,635 | — |
| — | President, Global Mfg/Tech Ops | 189,020 | — |
| — | President, Worldwide R&D | 185,074 | — |
| — | EVP, Chief Business Officer | 154,375 | — |
| — | Director | 127,426 | — |
| — | EVP, Chief Financial Officer | 123,314 | — |
| — | Director | 97,720 | — |
| — | EVP, Chief Technical Officer | 84,140 | — |
| — | EVP, Chief Legal Officer | 78,560 | — |
| — | EVP, Chief Commercial Officer | 66,767 | — |
| — | Chief Medical Officer | 52,172 | — |
| — | EVP, Chief R&D Officer | 51,818 | — |
| — | Director | 49,750 | — |
| — | Director | 49,360 | — |
| — | Director | 47,840 | — |
| — | EVP, Chief Financial Officer | 47,686 | — |
| — | Director | 46,440 | — |
| — | EVP, Chief Commercial Officer | 42,472 | — |
| — | Director | 41,940 | — |
| — | SVP, Chief Financial Officer | 41,089 | — |
| — | Director | 35,500 | — |
| — | Director | 35,000 | — |
| — | Director | 33,140 | — |
| — | Director | 32,750 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BMRN quote page; the site-wide leaderboard is on the insider transactions hub.